STEVANATO GROUP S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.32 USD | +3.83% |
|
+1.75% | -25.54% |
| Sales 2024 * | 1.13B 1.23B 1.67B | Sales 2025 * | 1.25B 1.36B 1.85B | Capitalization | 5.11B 5.55B 7.56B |
|---|---|---|---|---|---|
| Net income 2024 * | 132M 143M 195M | Net income 2025 * | 164M 178M 242M | EV / Sales 2024 * | 4.77 x |
| Net Debt 2024 * | 274M 297M 405M | Net Debt 2025 * | 248M 269M 367M | EV / Sales 2025 * | 4.28 x |
| P/E ratio 2024 * |
37.9
x | P/E ratio 2025 * |
30.4
x | Employees | 5,635 |
| Yield 2024 * |
0.34% | Yield 2025 * |
0.36% | Free-Float | 15.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on Stevanato Group S.p.A.
More recommendations
More press releases
More news
| 1 day | +3.83% | ||
| 1 week | +1.75% | ||
| 1 month | -24.21% | ||
| 3 months | -37.65% | ||
| 6 months | -25.87% | ||
| Current year | -25.54% |
1 week
19.02
20.89
1 month
18.8528.08
Current year
18.8534.73
1 year
18.8536.30
3 years
13.3636.30
5 years
13.3636.30
10 years
13.3636.30
| Managers | Title | Age | Since |
|---|---|---|---|
Franco Moro
CEO | Chief Executive Officer | 61 | 17-12-31 |
Marco Dal Lago
DFI | Director of Finance/CFO | 52 | 19-12-31 |
Franco Stevanato
CHM | Chairman | 51 | 09-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fabrizio Bonanni
BRD | Director/Board Member | 78 | 12-12-31 |
William Federici
BRD | Director/Board Member | 64 | 21-04-30 |
Donald Morel
BRD | Director/Board Member | 67 | 18-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.82% | 5 M€ | +15.85% | ||
| 2.43% | 142 M€ | +12.59% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.06% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 20.32 | +3.83% | 650,399 |
| 24-05-30 | 19.57 | +2.14% | 338,222 |
| 24-05-29 | 19.16 | -1.74% | 389,620 |
| 24-05-28 | 19.5 | -2.35% | 592,310 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm
More quotes
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Calendar
2024-06-04
- William Blair Growth Stock Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.32
USD
Average target price
28.91
USD
Spread / Average Target
+42.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.54% | 5.54B | |
| -7.16% | 178B | |
| -1.23% | 107B | |
| -4.86% | 67.04B | |
| -4.28% | 47.23B | |
| +10.32% | 44.62B | |
| +8.14% | 42.5B | |
| +15.53% | 25.22B | |
| -5.88% | 24.14B | |
| -5.38% | 23.69B |
- Stock Market
- Equities
- STVN Stock
